Oct 6 2009
Health Robotics today announced that it has signed an exclusive five-year strategic partnership with Grifols International S.A. for its revolutionary CytoCare Robot. The agreement enables Grifols to add CytoCare to its prior i.v.STATION(TM) contract with Health Robotics, and achieve its objective to safely, accurately and cost-effectively automate the preparation of Oncology I.V. Admixtures in Mexico, Chile, Brazil, Argentina, Uruguay, Paraguay, Bolivia, Peru, Venezuela, Colombia, Ecuador, Panama, Costa Rica, Belize, Nicaragua, El Salvador, Honduras, Guatemala, Surinam, French Guyana, and Guyana. In addition, the contract between the companies also adds Mexico to Grifols' i.v.STATION distribution and support rights after Health Robotics recently accomplished the termination of its last Devon Robotics contract.
While other companies have for many years made promises of robotic IV automation products, and even showcased marketing demonstrations of competing solutions that were supposed to exist as far back as twenty years ago, the fact remains that CytoCare is the only available solution that currently exists anywhere in the world to automatically compound and prepare ready-to-administer hazardous IV Admixtures for Oncology and other drug classes, and that has been proven to work in a "live" hospital pharmacy environment, instead of just marketing hype, sales brochures, and "staged" demonstrations at pharmaceutical trade symposiums such as ASHP and EAHP.
"We are very excited to have been chosen by Health Robotics as their exclusive CytoCare partner in Latin America, and to add one of the largest Latin American markets [Mexico] to our i.v.STATION distribution rights. CytoCare, the world's first and only robotic system designed for the safe and sterile preparation of patient-specific hazardous IV Admixtures, represents an ideal complement to our other market-leading Pharmacy Automation products. Health Robotics' two products will help our local service teams in Latin America differentiate our pharmacy solutions from both clinical and financial perspectives", stated Xavier Guix, VP of Marketing for Grifols' Hospital System Division".
"Grifols is the perfect fit for Health Robotics in Latin America due to their well-established distribution channels, their commitment to patient safety, their company stability and superior market footprint, and finally their world-class service infrastructure. In addition to the obvious success in expanding our partnership with Grifols and receiving a repeat endorsement from an existing Health Robotics' partner, I'm very pleased that this new contract symbolizes three significant milestones for Health Robotics: the final replacement of Devon as a local service provider for Health Robotics, the irrevocable termination of all contractual arrangements between the Devon International Group and Health Robotics, and lastly, the rapid and successful attainment of 95% distribution and support global coverage for our CytoCare robot, much needed after Devon's attempted disruptions to our customers due to their many litigations with their former financial partners in America and in Asia, such as HRNA and ITOCHU", stated Werner Rainer, Health Robotics' CEO
Children's Colorado earns prestigious cardiomyopathy recognition